AsianFin -- Insilico Medicine Inc., an AI-driven drug discovery startup, is exploring the possibility of an initial public offering (IPO) after securing $110 million in funding, pushing its valuation beyond $1 billion. This move underscores the growing investor interest in AI-powered pharmaceutical breakthroughs.
The U.S.-based company, which has significant operations in China, led its latest financing round with Value Partners Group, alongside existing investors such as Warburg Pincus, OrbiMed Advisors LLC, and Eli Lilly’s venture arm, according to a company statement.
Investor enthusiasm for generative AI startups has surged, particularly following China’s DeepSeek advancements, which have demonstrated global AI competitiveness, CEO Alex Zhavoronkov told Bloomberg News. With the Series E funding, Insilico’s valuation now stands well above $1 billion.
Insilico, along with competitors Atomwise Inc. and BenevolentAI, aims to revolutionize drug discovery—historically a costly and time-consuming process—with AI. While the technology has yet to fully meet its early promise in drug development, optimism remains high.
Explore more exclusive insights at nextfin.ai.